Analyst Reco. Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
2.84 ^USD	-1.73%		+4.80%	-67.69%

May. 10	Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating	MT
May. 10	Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating	May. 10	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating	May. 10	MT
Goldman Sachs Adjusts Price Target on Revance Therapeutics to $9 From $8, Maintains Neutral Rating	Mar. 01	MT
Needham Cuts Price Target on Revance Therapeutics to $18 From $20, Maintains Buy Rating	Feb. 29	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $20 From $42, Maintains Overweight Rating	Feb. 29	MT
Mizuho Securities Downgrades Revance Therapeutics to Neutral From Buy, Lowers Price Target to $9 From $16	Jan. 29	MT
Needham Cuts Price Target on Revance Therapeutics to $20 From $25, Maintains Buy Rating	Jan. 09	MT
Goldman Sachs Downgrades Revance Therapeutics to Neutral From Buy, Cuts Price Target to $8 From $30	Jan. 09	MT
Mizuho Adjusts Revance Therapeutics' Price Target to $16 From $35, Maintains Buy Rating	Nov. 22	MT
Piper Sandler Adjusts Revance Therapeutics' Price Target to $42 From $44, Maintains Overweight Rating	Nov. 09	MT
Needham Adjusts Revance Therapeutics Price Target to $25 From $35, Maintains Buy Rating	Nov. 09	MT
HC Wainwright Adjusts Revance Therapeutics' Price Target to $15 From $41, Keeps Buy Rating	Nov. 06	MT
Barclays Adjusts Revance Therapeutics' Price Target to $35 From $40, Maintains Overweight Rating	23-10-23	MT
Morgan Stanley Lowers Price Target on Revance Therapeutics to $12 From $25, Maintains Equalweight Rating	23-10-11	MT
Goldman Sachs Adjusts Revance Therapeutics' Price Target to $33 From $38, Keeps Buy Rating	23-09-21	MT
Piper Sandler Adjusts Price Target on Revance Therapeutics to $44 From $50, Maintains Overweight Rating	23-09-20	MT
Needham Adjusts Revance Therapeutics Price Target to $35 From $40, Maintains Buy Rating	23-09-20	MT
BNP Paribas Exane Upgrades Revance Therapeutics to Neutral From Underperform, Price Target is $20	23-08-16	MT
Morgan Stanley Adjusts Price Target on Revance Therapeutics to $25 From $26, Maintains Equal-Weight Rating	23-08-09	MT
Needham Adjusts Price Target on Revance Therapeutics to $40 From $44, Maintains Buy Rating	23-08-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Analyst Reco.

Filters